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underestimate can be created. Using estimates from a long-term
trial creates a downward bias in the event rates and potentially
affects the results and interpretation of a meta-analysis. Further-
more, potential imbalances in the pattern of events and censoring
will change the relative rates between the 2 groups.
A meta-analysis of all open artery hypothesis trials is certainly
reasonable, although the OAT and TOSCA-2 studies will dom-
inate such analyses of clinical outcomes and function respectively
because of their large numbers. A recently published meta-analysis
of the 6 trials that included only studies of patients with total
occlusions showed no effect of the study intervention on death,
MI, heart failure, or their composite (10). The Abbate et al. (1)
meta-analysis, with its selective inclusion and exclusion of studies,
methodological limitations of aggregate, nonpatient level data, and
the marked and statistically significant heterogeneity of popula-
tions, duration of follow-up and of treatment effect, contributes
little to inform medical practice.
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Reply
We welcome the letter of Dr. Džavı´k and colleagues and other
OAT (Occluded Artery Trial) study investigators in reference to
our recently published report (1) as it presents an occasion to
discuss, in a scholarly manner, the benefits of late revascularization
of the infarct-related artery (IRA) in patients with acute myocar-
dial infarction (AMI).
While Dr. Džavı´k and colleagues state that our meta-analysis
“misses the mark,” we conversely believe that they may have missed
the point of our analysis. This meta-analysis is not meant to be an
alternative to the OAT study but rather an integration of available
information to medical practice with a diverse assessment of the
question of whether revascularization of the IRA should be
attempted in patients presenting 12 h after AMI. This study is
not meant specifically to investigate whether there is a clinical
correlate to the “open artery hypothesis” (2), although in some
ways its findings support such hypotheses.
The OAT study (3) was designed to clinically test the “open artery
hypothesis” but failed to show any benefit or harm from late
revascularization. Enrollment, however, was stopped early, events
were fewer than anticipated, median follow-up was3 years, and the
cardiology community expressed concerns regarding the applicability
of the results to real-life scenarios. No detailed registry of the screened
patients has been taken in order to appraise the external validity of the
trial and compare outcomes of randomized versus nonrandomized
patients. It is unclear whether many occlusions that were deemed
feasible and functionally important were immediately attempted (thus
excluding them from randomization), with potentially less ideal
candidates available for randomization.
Approximately 1 year after publication of the OAT study, the
SWISSI II (Swiss Interventional Study on Silent Ischemia
Type II) study (4) showed a survival benefit for patients with
inducible ischemia after AMI randomized to late revasculariza-
tion of the IRA. Therefore, we attempted to put these disparate
results into perspective using the meta-analytic technique with the
belief that inclusion of multiple trials in the meta-analysis may
reduce the enrollment bias by including more investigators and
different patient pools, including patients with different degrees of
IRA stenosis.
We agree that our analysis is characterized by heterogeneity
among studies but we see this not as a flaw in the design but rather
an opportunity to detect differences in study designs, study
population, and, ultimately, results. We included in the analysis 10
studies randomizing patients to late revascularization of the IRA or
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medical therapy only. Four studies including 910 patients did not
require angiographic determination of total occlusion before ran-
domization resulting in the inclusion of some patients with
subtotal occlusion. Nevertheless, 84% of patients in the meta-
analysis had total occlusion, making it unlikely that the mortality
benefit was driven exclusively by the 16% of patients with subtotal
occlusion. Dr. Džavı´k and colleagues criticize this approach as they
think the analysis should have been limited to the 6 studies with
total occlusion. The criticism of mixing apples with oranges is not
uncommon but fails to appreciate the value of the meta-analytic
technique. While the presence of heterogeneity in a meta-analysis
requires more conservative tests to be performed (random effects
vs. fixed effects), it does not jeopardize the results of the analysis
while providing an opportunity for meta-regression looking for
covariables that may explain why different studies provided differ-
ent results (5–10). Using a metaphor, we argue that patients are
apples and oranges with many individual characteristics. Thus, a
study on only apples may not be useful when dealing with oranges,
whereas a study on fruit in general may be equally applicable and
appropriate for making inferences on apples as well as oranges. We
felt that it was better to include all studies and all patients, and
then perform a meta-regression to identify potential cofactors. If
we had not included the 4 studies we would have missed an
opportunity to analyze outcomes of 910 patients the majority of
which did have total IRA occlusion. The results of our analysis
suggest that, although a benefit exists in the entire cohort of
patients, those studies with more liberal angiographic inclusion
criteria were more likely to be positive than those with more strict
criteria, and, therefore, we learned not only that late revascular-
ization was associated with improved survival but also that patients
with subtotal occlusion may benefit the most. These findings are
consistent with the results of 2 individual studies, the ALKK
(Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte)
study (11) and the SWISSI II study (4), which enrolled patients
late after AMI independent of IRA status and showed a survival
benefit for late percutaneous coronary intervention. Furthermore,
we are not sure that total and subtotal occlusions are 2 different
disease processes as we believe that they are 2 presentations of the
same process and that significant functional and clinical overlap
exists between the 2 conditions.
Dr. Džavı´k and colleagues challenged our choice of studies to be
included stating that “thousands of additional patients in post-MI
revascularization studies” could have been included. They fail to
quote such studies. Perhaps they refer to the numerous studies
addressing the value of an early invasive versus early conservative
strategy for patients with acute coronary syndromes (12). If this
were the case, we would point out that such studies did not
randomize patients to late revascularization of the IRA after AMI
but rather on early and elective angiography versus delayed and
selective angiography in such patients, therefore not addressing the
question of whether revascularization of the IRA should be
attempted 12 h after AMI.
Dr. Džavı´k and colleagues also quote a recent meta-analysis by
Ioannidis et al. (13) recently published in the American Heart Jour-
nal, which we have commented on in a letter to the Editor (14).
While we first disagree with the authors of the meta-analysis
regarding the inclusion of the TOAT (The Open Artery Trial)
study (15), which had no true baseline cardiac dimension and
function assessment, most importantly we disagree with the overly
pessimistic interpretation of their results. Despite inclusion of the
TOAT study (15), the meta-analysis showed a 2% greater im-
provement in left ventricular ejection fraction (LVEF) with late
revascularization demonstrating, in our opinion, that a benefit
indeed exists. Moreover, the relative improvement in ejection
fraction goes up to 3% and an approximate 10% reduction in
ventricular volumes if the TOAT study is excluded, as we
published in a meta-analysis dedicated to assess effects on cardiac
remodeling and function in patients with total occlusion published
in Catheterization and Cardiovascular Intervention (16). Further-
more, neither our meta-analysis (1) nor the one from Ioannidis et
al. (13) confirmed the disturbing trend observed in the OAT trial
(3) regarding an increase in recurrent myocardial infarction in
revascularization patients, which at least supports the safety of a
revascularization approach. Regarding the TOAT study (15), we
dedicated an entire paragraph in our discussion to the exclusion of
this study. What was unexpected in the TOAT study was that
while revascularization patients had adverse remodeling they ex-
perienced an improvement in functional capacity. After contacting
the TOAT investigators, we decided not to include the TOAT
data because a potential early recovery in the revascularization arm
could have occurred before the “baseline” assessment, thus, biasing
the results. Interestingly enough, a substudy of the TOAT study
showed that patients with a significant amount of viable myocar-
dium showed more favorable remodeling after revascularization
suggesting that a subgroup of patients may indeed benefit from late
revascularization (17). The TAMI-6 (Thrombolysis and Angio-
plasty in Myocardial Infarction-6) study was excluded because
randomization occurred 6 to 24 h after AMI (18). Regarding the
inclusion of the BRAVE-2 (Beyond 12 Hours Reperfusion Alter-
native Evaluation) trial (19), we wish to make a simple consider-
ation that only 8 patients received bypass surgery rather than
percutaneous coronary intervention (which is unlikely to have
changed the 42-day outcome).
The comments regarding the use of statistical methods to
compare means rather than individual patient data is a method
accepted by most statistical authorities (20,21). We realize that the
presence of paired data or individual patient data would have been
optimal, but such data were not available even after contacting the
principal investigators of the individual studies, including the very
same Drs. Džavı´k, Steg, and Hochman. The bias toward healthier
patients in repeated analysis is inevitable but likely equally distrib-
uted between the 2 groups or perhaps more prominent in the
group with more events. Specifically, all patients in the SWISSI II
trial (4) that had an event were censored from the analysis of
LVEF. Considering that significantly more patients had an ad-
verse event in the medical group, less patients had available data at
follow-up in the medical group (36% vs. 72%). If we assume that
only the healthier patients had a repeat LVEF assessment, it is
obvious that this may have lead to an overestimation of LVEF in
the medical group more so than in the interventional group, thus
rendering the analysis even more conservative. The comment on
the Kaplan-Meier curve is incomplete if the authors fail to
recognize the limitations of the Kaplan-Meier curve, especially
when curves are extended beyond median survival (22,23).
In conclusion, our meta-analysis presents an overview of the
effect of late revascularization including the largest number of
patients to date (3,560 patients). We demonstrate that revascular-
ization of the IRA beyond the 12-h limit is associated with a
survival benefit. This observation is not in contrast with the OAT
study but rather shows that some patients may benefit more than
others. The same OAT study showed (in the online supplement
data only) that there was a benefit in terms of angina reduction
581JACC Vol. 52, No. 7, 2008 Correspondence
August 12, 2008:577–86
with revascularization up to 24 months, and in the TOSCA-2
(Total Occlusion Study of Canada) trial (24), a substudy of the
OAT study, there was a trend toward more favorable remodeling.
The results of the OAT study do not prove or disprove the
benefits of late revascularization in patients similar to the patients
in the OAT study and certainly do not apply to the entirety of
post-AMI patients. Unfortunately, despite the efforts of investi-
gators like the OAT Investigators, only 3,560 patients have been
randomized to date, and they may not be enough to draw
meaningful conclusions and/or identify subgroups of patients with
greatest benefit or risk from late revascularization.
We thank Dr. Džavı´k and colleagues for this opportunity to
clarify that our analysis was not designed to prove or disprove the
findings of the OAT study, which likely applies to a minority of
patients after AMI. Instead, we set out to analyze all available
evidence and demonstrated the benefit of late revascularization of
the IRA late after AMI.
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Percutaneous Coronary
Intervention or Coronary Artery
Bypass Graft for Unprotected
Left Main Coronary Artery
Disease: The Endless Debate
The “state-of-the art” paper written by Taggart et al. (1) calls into
question the current evidence in support of percutaneous coronary
intervention (PCI) for the treatment of unprotected left main stem
disease. In view of the fact that current guidelines still indicate
coronary artery bypass grafting (CABG) as the “standard of care,”
the authors conclude that the use of drug-eluting stents (DES) in
“off-label” cases should be discouraged and that good surgical
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